Alnylam Pharmaceuticals has been granted a patent for double stranded RNA agents targeting the Huntingtin gene to treat Huntington’s disease. The patent covers specific nucleotide sequences and compositions for inhibiting HTT expression in cells. GlobalData’s report on Alnylam Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Alnylam Pharmaceuticals, siRNA gene silencing was a key innovation area identified from patents. Alnylam Pharmaceuticals's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for dsrna agent inhibiting expression of htt
A recently granted patent (Publication Number: US11993774B2) discloses a double-stranded ribonucleic acid (dsRNA) agent designed to inhibit the expression of the Huntingtin (HTT) gene in cells. The dsRNA agent consists of a sense strand and an antisense strand forming a double-stranded region, with specific nucleotide sequences outlined in the patent claims. The sense strand contains at least 15 contiguous nucleotides that closely match a specified sequence, while the antisense strand also follows a similar pattern with minimal nucleotide differences. The patent further details variations in the nucleotide sequences, highlighting the importance of specific configurations for effective gene inhibition.
Moreover, the patent encompasses the use of the dsRNA agent in isolated cells and pharmaceutical compositions aimed at inhibiting HTT gene expression. The compositions can be formulated in both unbuffered and buffered solutions, with specific buffer solutions mentioned in the claims. The patent also includes variations in the length and nucleotide differences in the sense and antisense strands, emphasizing the precision required for optimal gene inhibition. Overall, the patent provides a detailed framework for utilizing the dsRNA agent to target the HTT gene, potentially offering new avenues for therapeutic interventions in conditions associated with HTT gene dysregulation.
To know more about GlobalData’s detailed insights on Alnylam Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
